Meeting
2022 ASCO Annual Meeting
Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET).
Authors
Adam Brufsky
University of Pittsburgh Medical Center, Pittsburgh, PA
Adam Brufsky , Lauren Lenz , Anita Pudusseri , David Wright , Kashyap B. Patel , Brad T. Clifford , Tracey L. O'Connor , Sasha Strain , Fadi Kayali , Sarah Ratzel , Shelly Cummings , Ralf Kronenwett , Thomas Paul Slavin Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT04016935
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 537)
DOI
10.1200/JCO.2022.40.16_suppl.537
Abstract #
537
Poster Bd #
309
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2024 ASCO Annual Meeting
Predicting epirubicin response in Danish patients with breast cancer.
First Author: Ida Kappel Buhl
First Author: Mafalda Oliveira